Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Scleroderma Therapeutics Market

Scleroderma Therapeutics Market Share

Report ID: GMI10981
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Scleroderma Therapeutics Market Share

The market has seen significant industrial developments, including the introduction of novel biologics and targeted therapies. Companies are increasingly focusing on immunosuppressors and antifibrotic agents to manage the disease's complex symptoms. Recent advancements include the FDA approval of Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease, highlighting a trend towards more specialized treatments. Collaborative research initiatives and partnerships are accelerating the development of new drugs. Additionally, the market is witnessing increased investment in clinical trials aimed at expanding the indications for existing drugs. These developments are enhancing treatment options and improving patient outcomes, driving the market forward.

Scleroderma Therapeutics Market Companies

Prominent players operating in the scleroderma therapeutics industry include:

Actelion (Johnson & Johnson)
Akashi Therapeutics
Astellas Pharma
Bayer AG
Boehringer Ingelheim
Bristol-Myers Squibb
Galderma Laboratories
Genkyotex
Gilead Sciences
GSK plc
Pfizer, Inc.
Prometic Life Sciences, Inc.
F. Hoffmann La Roche Ltd.
Sanofi SA
United Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Scleroderma therapeutics market size was USD 2.2 billion in 2023 and is expected to register 6.8% CAGR from 2024-2032 due to increasing prevalence of the condition and rising awareness amongst patients worldwide.

Scleroderma therapeutics industry from the immunosuppressors segment reached USD 781.6 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their pivotal role in managing systemic scleroderma.

North America scleroderma therapeutics industry is expected to register 5.3% CAGR from 2024-2032 due to increasing prevalence of the disease and heightened awareness among healthcare professionals and patients in the region.

Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Galderma Laboratories, Genkyotex, Gilead Sciences, GSK plc, Pfizer, Inc., Prometic Life Sciences, Inc., F. Hoffmann La Roche Ltd., Sanofi SA, and United Therapeutics, are some of the major scleroderma therapeutics companies worldwide.